AU2017295071B2 - Methods and compositions for the treatment of cancer - Google Patents

Methods and compositions for the treatment of cancer Download PDF

Info

Publication number
AU2017295071B2
AU2017295071B2 AU2017295071A AU2017295071A AU2017295071B2 AU 2017295071 B2 AU2017295071 B2 AU 2017295071B2 AU 2017295071 A AU2017295071 A AU 2017295071A AU 2017295071 A AU2017295071 A AU 2017295071A AU 2017295071 B2 AU2017295071 B2 AU 2017295071B2
Authority
AU
Australia
Prior art keywords
polypeptide
seq
arg
lys
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017295071A
Other languages
English (en)
Other versions
AU2017295071A1 (en
Inventor
Marie-Eve Beaulieu
Toni JAUSET GONZÁLEZ
Laura Soucek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institució Catalana de Recerca i Estudis Avançats
Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
Original Assignee
Institució Catalana de Recerca i Estudis Avançats
Fundació Privada Institut d'Investigació Oncològica Vall-Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institució Catalana de Recerca i Estudis Avançats, Fundació Privada Institut d'Investigació Oncològica Vall-Hebron filed Critical Institució Catalana de Recerca i Estudis Avançats
Publication of AU2017295071A1 publication Critical patent/AU2017295071A1/en
Application granted granted Critical
Publication of AU2017295071B2 publication Critical patent/AU2017295071B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017295071A 2016-07-15 2017-07-17 Methods and compositions for the treatment of cancer Active AU2017295071B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382339.6 2016-07-15
EP16382339.6A EP3269734A1 (en) 2016-07-15 2016-07-15 Methods and compositions for the treatment of cancer
PCT/EP2017/067998 WO2018011433A1 (en) 2016-07-15 2017-07-17 Methods and compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2017295071A1 AU2017295071A1 (en) 2019-01-31
AU2017295071B2 true AU2017295071B2 (en) 2022-06-09

Family

ID=56497695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017295071A Active AU2017295071B2 (en) 2016-07-15 2017-07-17 Methods and compositions for the treatment of cancer

Country Status (21)

Country Link
US (1) US11427621B2 (enExample)
EP (2) EP3269734A1 (enExample)
JP (1) JP7090593B2 (enExample)
KR (1) KR102232500B1 (enExample)
CN (1) CN109563151B (enExample)
AU (1) AU2017295071B2 (enExample)
BR (1) BR112019000732A2 (enExample)
EA (1) EA201990298A1 (enExample)
ES (1) ES2985967T3 (enExample)
HR (1) HRP20241153T1 (enExample)
HU (1) HUE067973T2 (enExample)
IL (1) IL264176B2 (enExample)
MA (1) MA45675B1 (enExample)
MD (1) MD3484913T2 (enExample)
MX (1) MX2019000346A (enExample)
PL (1) PL3484913T3 (enExample)
RS (1) RS65983B1 (enExample)
SG (1) SG11201900021PA (enExample)
SM (1) SMT202400360T1 (enExample)
WO (1) WO2018011433A1 (enExample)
ZA (1) ZA201900960B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101729826B1 (ko) * 2015-01-09 2017-05-11 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101862239B1 (ko) * 2016-07-07 2018-05-30 주식회사 동희산업 플라스틱 연료탱크의 제조방법
KR101859583B1 (ko) * 2016-07-07 2018-06-27 주식회사 동희산업 플라스틱 연료탱크의 제조방법
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer
EP3841114A4 (en) * 2018-08-20 2022-06-08 Helix Nanotechnologies, Inc. METHODS AND COMPOSITIONS FOR RNA EXPRESSION OF MYC INHIBITORS
CA3133155A1 (en) * 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
TWI829893B (zh) * 2019-03-19 2024-01-21 瓦爾希伯倫私人腫瘤研究基金會 診斷肺癌的方法
KR102922015B1 (ko) * 2019-10-17 2026-02-04 주식회사 나이벡 Fer 티로신 키나아제 결합능이 있는 신규한 펩타이드 및 이의 용도
KR102398339B1 (ko) * 2020-01-09 2022-05-13 이화여자대학교 산학협력단 일산화질소 전달용 융합 펩타이드 및 이의 용도
WO2021208787A1 (zh) * 2020-04-15 2021-10-21 徐荣臻 用于筛选药物的靶标多肽和筛选方法
EP4361633A1 (en) 2022-10-25 2024-05-01 Peptomyc, S.L. Method for predicting response to a cancer treatment
EP4446742A1 (en) 2023-04-14 2024-10-16 Peptomyc, S.L. Method for assessing or monitoring the response to a cancer treatment
EP4473974A1 (en) * 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027314A1 (en) * 1995-07-31 2003-02-06 Vinson Charles R. Extension of a protein-protein interaction surface to inactivate the function of a cellular protein

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
ES2356342T3 (es) 1998-01-05 2011-04-07 The University Of Washington Mejora de transporte utilizando agentes de alteración de membrana.
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
WO2013063560A2 (en) 2011-10-27 2013-05-02 New York University INHIBITION OF c-MYC UBIQUITINATION TO PREVENT CANCER INITIATION AND PROGRESSION
EP2801370A1 (en) * 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
EP3269734A1 (en) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods and compositions for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027314A1 (en) * 1995-07-31 2003-02-06 Vinson Charles R. Extension of a protein-protein interaction surface to inactivate the function of a cellular protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Database REFSEQ [online] 27 May 2016, "myc proto-oncogene protein isoform X1, partial [Cricetulus griseus]" XP55413005, Database accession no. XP_003516054. *
DATABASE UniProt [online] 16 March 2016 (2016-03-16), "SubName: Full=Myc proto-oncogene protein {ECO:0000313|EMBL:EHB05990.1};", XP002774402, retrieved from EBI *
Database UniPROT [online] 16 March 2016 , "SubName: Full=C-myc {ECO:0000313EMBL:AAQ57178.1}; Flags: Fragment;", XP55413001, retrieved from EBI accession no. UNIPROT: Q6WDE6, Database accession no. Q6WDE6, URL: EBI *

Also Published As

Publication number Publication date
HRP20241153T1 (hr) 2024-11-22
EP3269734A1 (en) 2018-01-17
MA45675A (fr) 2021-04-21
MA45675B1 (fr) 2024-07-31
CN109563151B (zh) 2023-03-07
EP3484913C0 (en) 2024-07-03
KR20190032427A (ko) 2019-03-27
MX2019000346A (es) 2019-04-01
CN109563151A (zh) 2019-04-02
EA201990298A1 (ru) 2019-06-28
RS65983B1 (sr) 2024-10-31
WO2018011433A1 (en) 2018-01-18
IL264176A (en) 2019-02-28
JP2019525753A (ja) 2019-09-12
EP3484913B1 (en) 2024-07-03
PL3484913T3 (pl) 2025-01-07
IL264176B2 (en) 2023-07-01
MD3484913T2 (ro) 2024-10-31
SMT202400360T1 (it) 2024-11-15
KR102232500B1 (ko) 2021-03-26
US11427621B2 (en) 2022-08-30
ZA201900960B (en) 2020-05-27
IL264176B1 (en) 2023-03-01
CA3029781A1 (en) 2018-01-18
EP3484913A1 (en) 2019-05-22
US20200247857A1 (en) 2020-08-06
HUE067973T2 (hu) 2024-11-28
SG11201900021PA (en) 2019-01-30
JP7090593B2 (ja) 2022-06-24
AU2017295071A1 (en) 2019-01-31
BR112019000732A2 (pt) 2019-07-30
ES2985967T3 (es) 2024-11-08

Similar Documents

Publication Publication Date Title
EP3484913B1 (en) Methods and compositions for the treatment of cancer
US11339205B2 (en) Methods and compositions for the treatment of cancer
CA3029781C (en) Methods and compositions for the treatment of cancer
HK40007694B (en) Methods and compositions for the treatment of cancer
HK40007694A (en) Methods and compositions for the treatment of cancer
EA042570B1 (ru) Способы и композиции для лечения рака
HK40014958A (en) Methods and compositions for the treatment of cancer
HK1219756B (en) Methods and compositions for the treatment of cancer
EA047076B1 (ru) Способы и композиции для лечения рака
WO2005037297A1 (en) Compositions and methods for inhibiting cell senescence and hyperproliferative disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)